Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01843127 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01843127 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 24 participants.
The verdict
NCT01843127, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
To explore the mechanism of action of ranolazine as a potential treatment for type 2 diabetes mellitus (T2DM).
Interventions
- DRUG Placebo
- DRUG Ranolazine
- DRUG Exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-04 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01843127
The ClinicalTrials.gov registry entry for NCT01843127 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01843127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01843127 about?
NCT01843127 is a clinical study titled "A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.". To explore the mechanism of action of ranolazine as a potential treatment for type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT01843127?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-04. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01843127?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG), Exenatide (DRUG).
Who is sponsoring clinical trial NCT01843127?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.